ABL Bio Inc.
A global leader in bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases.
64 employees · est. 2016 · Korea South
Light Chain Bioscience | Novimmune SA
Light Chain Bioscience – A brand of Novimmune SA
76 employees · est. 1998 · Plan-les-ouates, Switzerland
Light Chain Bioscience | Novimmune SA is the older company (2016 vs 1998).
Side-by-Side Comparison
| Metric | ABL Bio Inc. | Light Chain Bioscience | Novimmune SA |
|---|---|---|
| Founded | ||
| Founded | 2016 | 1998 older |
| Headquarters | ||
| Headquarters | Korea South | Plan-les-ouates, Switzerland |
| Employees | ||
| Employees | 64 | 76 |
| Industry | ||
| Industry | Biotechnology, Health Care | Biotechnology, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | IPO | Series C |
| Total Funding | ||
| Total Funding | $49.12B | Not tracked yet |
| Funding Rounds | ||
| Funding Rounds | 6 | Not tracked yet |
| Services | ||
| Services | Development of innovative therapeutic drugs, Research and development of cancer and neurodegenerative disease treatments, Creating and managing biopharmaceutical platforms, Clinical trials and regulatory approval processes | Development of bispecific therapeutics, Safe and selective targeting of CD47 and CD28, Antibody-based therapeutic solutions |
| Target Customers | ||
| Target Customers | Healthcare providers, Patients with cancer and neurodegenerative diseases, Pharmaceutical companies, Medical researchers | Oncologists, Pharmaceutical companies, Research institutions |
| Taxonomy | ||
| Taxonomy | Bispecific Antibody Therapeutics, Immuno-Oncology, Neurodegenerative Diseases, Grabody-T, Grabody-I, Grabody-B, 4-1BB Engagement, Blood-Brain Barrier Penetration, Clinical Stage Drug Candidates, Pre-Clinical Stage Drug Candidates, Antibody Drug Conjugate, CNS Targets, Strategic Partnerships, Next-Generation Antibody | Bispecific Antibodies, Multispecific Antibodies, Antibody Drug Discovery, Kappa-Lambda-Body Technology, Native Human Antibodies, Preclinical Drug Candidates, Clinical Drug Candidates, Immunology, Drug Development, Novel Therapeutics, Antibody Therapeutics, Biotechnology Award Winner |
| Website | ||
| Website | ablbio.com | lightchainbio.com |
About ABL Bio Inc.
ABL Bio Inc., founded in 2016 and headquartered in Korea South, stands as a prominent figure in the biotechnology space. Known for being a global leader in bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases, the company has carved out a niche in delivering innovative...
About Light Chain Bioscience | Novimmune SA
Light Chain Bioscience, a brand of Novimmune SA, is a Swiss-based company established in 1998 that operates at the forefront of Biotechnology and Pharmaceutical industries. Having transitioned key assets through divestment to EmaCo AG, Novimmune is refocusing on its proprietary bispecific technology...
We will tell you when either one moves
BounceWatch watches ABL Bio Inc. and Light Chain Bioscience | Novimmune SA for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at ABL Bio Inc. and Light Chain Bioscience... — by email.
Frequently Asked Questions
Compare ABL Bio Inc. with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at ABL Bio Inc. on 15 Jun 2026, and Light Chain Bioscience | Novimmune SA on 12 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
